Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anatara LifesciencesASX:ANR 3-Year EBITDA Growth Rate is 32.10% as of Dec. 2025, which is 44% above its 10-year median of 22.30. The stock has 5 warning signs investors should review. Among 1,127 Biotechnology companies, Anatara Lifesciences ranks better than 70.1% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 32.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 30.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 15.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Anatara Lifesciences was 37.30% per year. The lowest was -44.90% per year. And the median was 22.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Anatara Lifesciences 3-Year EBITDA Growth Rate Related Terms
ASX:ANR vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Anatara Lifesciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anatara Lifesciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anatara Lifesciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Anatara Lifesciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 32.10% mean?
Anatara Lifesciences (ASX:ANR) has a 3-Year EBITDA Growth Rate of 32.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Anatara Lifesciences and its competitors. This is 44% above median its historical median of 22.30. According to the industry distribution chart, Anatara Lifesciences ranks #337 out of 1127 companies in the Biotechnology industry, placing it in the top 29.9%.
Is Anatara Lifesciences' 3-Year EBITDA Growth Rate too high?
Anatara Lifesciences' current 3-Year EBITDA Growth Rate of 32.10% is 44% above median its 10-year median of 22.30. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Anatara Lifesciences' value of 32.10% is 115.4% above this industry median. Based on the distribution chart, Anatara Lifesciences ranks #337 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint.
How does Anatara Lifesciences' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anatara Lifesciences ranks #337 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Anatara Lifesciences in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Anatara Lifesciences' value of 32.10% is 115.4% above this benchmark. While the company's 10-year median is 22.30 vs. the industry median of 14.90, Anatara Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anatara Lifesciences's current 3-Year EBITDA Growth Rate of 32.10% is 115.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Anatara Lifesciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anatara Lifesciences's current 3-Year EBITDA Growth Rate is 32.10%, which is 44% above median its own 10-year median of 22.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anatara Lifesciences stock overvalued right now?
Anatara Lifesciences (ASX:ANR) has a current 3-Year EBITDA Growth Rate of 32.10%. The current 3-Year EBITDA Growth Rate is 32.10%, which is 44% above median its 10-year median of 22.30 and 115.4% above the Biotechnology industry median of 14.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Anatara Lifesciences (ASX:ANR), the current 3-Year EBITDA Growth Rate is 32.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anatara Lifesciences Ltd develops and commercializes evidence-based products addressing unmet needs in gastrointestinal health. The company focuses on building a pipeline of human health products, particularly targeting complex gastrointestinal conditions. It operates through a single reportable segment encompassing the research and development of oral solutions for gastrointestinal diseases and the commercialization of Detach, a diarrhea treatment for piglets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ANR has been successfully added to your 
